European Comission waived the pre-deciced commitments proposed by Takeda for the approval of its acquisition of Shire in 2018.
The Commision had approved the acquisition in 2018 subject to the divestiture of a particular drug developed by Shire, to treat inflammatory bowel diseases (IBD). Afterwards Takeda requested Commission to waive the commitments following certain circumstances in the market. The Comission carried out a market investigation and found out that; several permanent, significant and unforeseeable developments has taken place during the divestiture process, affecting both the evolution of the competitive landscape in IBD treatments. Accordingly the Commission came to the conclusion that the divestiture is no longer necessary for the acquisition and decided to waive them. (European Commission – 28.05.2020)
|
NAZALI TAX & LEGAL |